The AAT-AD/PD™ Focus Meeting 2018 was held in Turin, Italy, March 15-18, 2018. During the new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and AD/PD,TM the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer's, Parkinson's, and other related neurological disorders were at the forefront of the meeting. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
Improve your knowledge in the field of psychiatry by taking Elsevier's complimentary pain medicine continuing medical education courses.
This is a two-part CME activity with Part 1 highlighting real-world approaches to patient care utilizing design intelligent patients who have realistic and consistent human-to-human interaction and communication skills, opening possibilities for clinical psychosocial applications that address interviewing skills, diagnostic assessment and therapy training. The platform provides real-time feedback for continuous assessment and creates a personalized learning experience by presenting learners with data regarding their performance against peers. Part 2 of this activity is an Expert Exchange webcast that provides learners with a concise educational experience featuring two clinical experts exploring real-world approaches to patient care.
AAIC 2017: AN UPDATE ON SCIENTIFIC ADVANCES AND CLINICAL STRATEGIES IN ALZHEIMER’S DISEASE FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE®Format: Conference Reporter
The Alzheimer’s Association International Conference® 2017 (AAIC®) was held in London, England, July 16-20, 2017. As the largest international meeting dedicated to advancing dementia science, AAIC unites leaders from more than 70 countries to discuss the latest dementia study results and theories. In this activity, 2 experts summarize the key learnings from this year’s conference.
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with TolerabilityFormat: Webcast
Effective treatment of major depressive disorder with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and, often, intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. The latest data on multimodal therapies indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and neurotransmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.